HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements.

Michal Mielcarek; Daniel Zielonka; Alisia Carnemolla; Jerzy T Marcinkowski; Fabien Guidez

doi:10.3389/fncel.2015.00042

HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements.

Michal Mielcarek, Daniel Zielonka, Alisia Carnemolla, Jerzy T Marcinkowski, Fabien Guidez

Research output: Contribution to journal › Article › peer-review

85 Citations (Scopus)

242 Downloads (Pure)

Abstract

For the past decade protein acetylation has been shown to be a crucial post-transcriptional modification involved in the regulation of protein functions. Histone acetyltransferases (HATs) mediate acetylation of histones which results in the nucleosomal relaxation associated with gene expression. The reverse reaction, histone deacetylation, is mediated by histone deacetylases (HDACs) leading to chromatin condensation followed by transcriptional repression. HDACs are divided into distinct classes: I, IIa, IIb, III, and IV, on the basis of size and sequence homology, as well as formation of distinct repressor complexes. Implications of HDACs in many diseases, such as cancer, heart failure, and neurodegeneration, have identified these molecules as unique and attractive therapeutic targets. The emergence of HDAC4 among the members of class IIa family as a major player in synaptic plasticity raises important questions about its functions in the brain. The characterization of HDAC4 specific substrates and molecular partners in the brain will not only provide a better understanding of HDAC4 biological functions but also might help to develop new therapeutic strategies to target numerous malignancies. In this review we highlight and summarize recent achievements in understanding the biological role of HDAC4 in neurodegenerative processes.

Original language	Undefined/Unknown
Journal	Frontiers in cellular neuroscience
Volume	9
Issue number	42
DOIs	https://doi.org/10.3389/fncel.2015.00042
Publication status	Published - 24 Feb 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fncel.2015.00042Licence: CC BY

fncel-09-00042Final published version, 1.98 MBLicence: CC BY

http://www.frontiersin.org/cellular_neuroscience/10.3389/fncel.2015.00042/abstract

Cite this

@article{591efd43ccd844cb862fea13d420754c,

title = "HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements.",

abstract = "For the past decade protein acetylation has been shown to be a crucial post-transcriptional modification involved in the regulation of protein functions. Histone acetyltransferases (HATs) mediate acetylation of histones which results in the nucleosomal relaxation associated with gene expression. The reverse reaction, histone deacetylation, is mediated by histone deacetylases (HDACs) leading to chromatin condensation followed by transcriptional repression. HDACs are divided into distinct classes: I, IIa, IIb, III, and IV, on the basis of size and sequence homology, as well as formation of distinct repressor complexes. Implications of HDACs in many diseases, such as cancer, heart failure, and neurodegeneration, have identified these molecules as unique and attractive therapeutic targets. The emergence of HDAC4 among the members of class IIa family as a major player in synaptic plasticity raises important questions about its functions in the brain. The characterization of HDAC4 specific substrates and molecular partners in the brain will not only provide a better understanding of HDAC4 biological functions but also might help to develop new therapeutic strategies to target numerous malignancies. In this review we highlight and summarize recent achievements in understanding the biological role of HDAC4 in neurodegenerative processes.",

author = "Michal Mielcarek and Daniel Zielonka and Alisia Carnemolla and Marcinkowski, {Jerzy T} and Fabien Guidez",

year = "2015",

month = feb,

day = "24",

doi = "10.3389/fncel.2015.00042",

language = "Undefined/Unknown",

volume = "9",

journal = "Frontiers in cellular neuroscience",

issn = "1662-5102",

publisher = "Frontiers Media S.A.",

number = "42",

}

TY - JOUR

T1 - HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements.

AU - Mielcarek, Michal

AU - Zielonka, Daniel

AU - Carnemolla, Alisia

AU - Marcinkowski, Jerzy T

AU - Guidez, Fabien

PY - 2015/2/24

Y1 - 2015/2/24

N2 - For the past decade protein acetylation has been shown to be a crucial post-transcriptional modification involved in the regulation of protein functions. Histone acetyltransferases (HATs) mediate acetylation of histones which results in the nucleosomal relaxation associated with gene expression. The reverse reaction, histone deacetylation, is mediated by histone deacetylases (HDACs) leading to chromatin condensation followed by transcriptional repression. HDACs are divided into distinct classes: I, IIa, IIb, III, and IV, on the basis of size and sequence homology, as well as formation of distinct repressor complexes. Implications of HDACs in many diseases, such as cancer, heart failure, and neurodegeneration, have identified these molecules as unique and attractive therapeutic targets. The emergence of HDAC4 among the members of class IIa family as a major player in synaptic plasticity raises important questions about its functions in the brain. The characterization of HDAC4 specific substrates and molecular partners in the brain will not only provide a better understanding of HDAC4 biological functions but also might help to develop new therapeutic strategies to target numerous malignancies. In this review we highlight and summarize recent achievements in understanding the biological role of HDAC4 in neurodegenerative processes.

AB - For the past decade protein acetylation has been shown to be a crucial post-transcriptional modification involved in the regulation of protein functions. Histone acetyltransferases (HATs) mediate acetylation of histones which results in the nucleosomal relaxation associated with gene expression. The reverse reaction, histone deacetylation, is mediated by histone deacetylases (HDACs) leading to chromatin condensation followed by transcriptional repression. HDACs are divided into distinct classes: I, IIa, IIb, III, and IV, on the basis of size and sequence homology, as well as formation of distinct repressor complexes. Implications of HDACs in many diseases, such as cancer, heart failure, and neurodegeneration, have identified these molecules as unique and attractive therapeutic targets. The emergence of HDAC4 among the members of class IIa family as a major player in synaptic plasticity raises important questions about its functions in the brain. The characterization of HDAC4 specific substrates and molecular partners in the brain will not only provide a better understanding of HDAC4 biological functions but also might help to develop new therapeutic strategies to target numerous malignancies. In this review we highlight and summarize recent achievements in understanding the biological role of HDAC4 in neurodegenerative processes.

U2 - 10.3389/fncel.2015.00042

DO - 10.3389/fncel.2015.00042

M3 - Article

SN - 1662-5102

VL - 9

JO - Frontiers in cellular neuroscience

JF - Frontiers in cellular neuroscience

IS - 42

ER -